| 达比加群酯在抗凝治疗中的研究进展 |
| |
| 引用本文： | 赵沿祥,刘芳,王营. 达比加群酯在抗凝治疗中的研究进展[J]. 医学与哲学(人文社会医学版), 2011, 0(8): 36-37 |
| |
| 作者姓名： | 赵沿祥 刘芳 王营 |
| |
| 作者单位： | [1]山东中医药大学,山东济南250014 [2]山东中医药大学第二附属医院心脏中心,山东济南250001 |
| |
| 摘 要： | 新型口服抗凝药达比加群酯具有强效抗凝、出血风险低、无需特殊监测、药物相互作用少等优点，能显著降低卒中和栓塞性疾病的风险，同时显著降低出血事件的发生和血管性死亡率。它的问世是抗凝治疗领域和潜在致死性血栓预防领域的一项重大进展。
|
| 关 键 词： | 达比加群酯 抗凝治疗 非瓣膜性房颤 静脉血栓栓塞 |
Advances in Research in Treatment of Anticoagulant by Dabigatran Etexilate |
| |
| ZHAO Yan-xiang,LIU Fang,WANG Ying. Advances in Research in Treatment of Anticoagulant by Dabigatran Etexilate[J]. Medicine & Philosophy:Humanistic & Social Medicine Edition, 2011, 0(8): 36-37 |
| |
| Authors: | ZHAO Yan-xiang LIU Fang WANG Ying |
| |
| Affiliation: | . (Shandong University of Traditional Chinese Medicine, Jinan 250014,China) |
| |
| Abstract: | New oral direct thrombin inhibitors Dabigatran Etexilate has the advantages of potent anticoagulation,low risk of bleeding,no special monitoring and less drug interactions ,which can significantly reduce the risk of stroke, systemic embolism,vascular events, bleeding events and vascular mortality in patients with non-valvular atrial fibrillation, it is a major advance in anticoagulant therapy field and potentially deadly clots prevention fields. |
| |
| Keywords: | Dabigatran Etexilate anticoagulant therapy non-valvular atrial fibrillation venous thromboembolism |
| 本文献已被 维普 等数据库收录！ |
|
